Biotech

Top Biotech Stocks of 2017

Nearing the end of the year INN takes a look at the top gaining biotech stocks in the mid to small cap range for the NASDAQ and the TSX.

When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates. Gains for investors can be hard to find on the mid to small cap area of the industry. However, this year there was no shortage of companies achieving success and moving up the ranks.
One of the major things investors should be on the lookout moving into 2018 is the possibility of more acquisition deals from the bigger players in the industry with smaller companies advancing different aspects of their platforms.
As such the Investing News Network (INN) takes a closer look at the companies creating the biggest gains for their shareholders throughout 2017. This list includes companies with market caps between $50 and $500 million on the NASDAQ and the TSX.

NASDAQ

3. Viking Therapeutics (NASDAQ:VKTX)
Viking Therapeutics is focused exclusively on the development of therapies for the metabolic and endocrine disorders. Near the end of the year the company provided a critical topline data update to their phase 2 study of VK5211 with patients recovering from hip fracture.
“We are gratified to see VK5211 produce such robust pharmacologic effects along with a promising safety profile in this challenging population,” Dr. Brian Lian, CEO of Viking said.
In 2017, Viking Therapeutics saw a 245.38 percent increase to its stock price.
2. AVEO Oncology (NASDAQ:AVEO)
With three oncology candidates on different trials at several stages of the development pipeline, AVEO is fully exploring the options on this rapidly expansive side of the biotech industry.
The company has gone through the year with a steady stream of accomplishments in terms of their trials. Including an approval from the European Commission for FOTIVDA (tivozanib) treating adult patients with advanced renal cell carcinoma.
AVEO is also expecting results from a study of FOTIVDA in subjects with refractory advanced renal cell carcinoma for US approval in the first quarter of 2018.
Year-to-date the company has seen their share price increase by 443.52 percent.
1. Xoma (NASDAQ:XOMA)
The company uses an alternative strategy by not creating candidates themselves but seeking “transactions where it could exchange cash or equity today for future milestones and royalties.”
As part of their third quarter report to investors Jim Neal, CEO of XOMA said the company was in a position to deliver sustained growth in the years ahead thanks to over a dozen partner-funded programs.
In 2017 the company enjoyed a 656.4 percent increase to its share price.

top pharma stocks tsxTSX

3. Oncolytics Biotech (TSX:ONC)
This past year was a transitional one for Oncolytics, as told to INN by Michael Moore, vice president of investor relations and corporate communications for the company.
“As of November 2016, the company was tasked with recreating itself around the same asset and a new understanding of the technology, all with a new management team,” Moore said.
Moore also told INN the big jump for Oncolytics came thanks to the data from a randomized phase 2 trial on metastatic breast cancer for their candidate REOLYSIN. This new proposition worked for the company, pushing its share price up by 167.92 percent year-to-date.
2. Immunovaccine (TSX:IMV)
This company is working on the way we use our immune system for protection against serious diseases. Their DepoVax platform allows the company to work on several working agents.
As explained on its 2017 third quarter financials, the company received clearance from Health Canada on their phase 2 trial investigating DPX-Survivac, mCPA and Merck’s checkpoint inhibitor, pembrolizumab in combination against diffuse large B-cell lymphoma.
In 2017 the share price of Immunovaccine went up 267.65 percent.
1. Fennec Pharmaceuticals (TSX:FRX)
Despite its name, Fennec is focused on the biotech business with the development of their lead candidate PEDMARKTM (a unique formulation of sodium thiosulfate (STS)). The company has completed two pediatric phase 3 studies and plans to file for approval of its candidate in 2018.
In its most recent quarterly report, the company announced the data from its SIOPEL 6 study demonstrated the addition of STS “significantly reduces the incidence of cisplatin-induced hearing loss without any evidence of tumor protection.”
Fennec has seen a 351.34 percent increase to its share value so far in 2017.
Don’t forget to follow us @INN_LifeScience for real-time news updates.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Featured
Amgen today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63 rd American Society of Hematology Annual Meeting & Exposition in Atlanta, Georgia and virtually, from Dec. 11-14, 2021 . "The data being presented at ASH demonstrates Amgen's commitment to reaching more patients with our innovative hematology medicines and improving the patient experience by exploring more ...

- Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63 rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia and virtually, from Dec. 11-14, 2021 .

"The data being presented at ASH demonstrates Amgen's commitment to reaching more patients with our innovative hematology medicines and improving the patient experience by exploring more convenient administrations for people living with blood cancers," said David M. Reese , M.D., executive vice president of Research and Development at Amgen. "By accelerating the development and delivery of transformative medicines in difficult to treat and vulnerable patient populations, including children and pregnant women, we continue to focus on the relentless pursuit of breakthroughs for blood cancer patients and their families."

read more Show less
ABBVie today announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib achieved both primary endpoints of clinical remission a,b and endoscopic response c at week 12. 1 The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy, with over 60 percent having previously failed two or more ...

ABBVie (NYSE: ABBV) today announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission a,b and endoscopic response c at week 12. 1 The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy, with over 60 percent having previously failed two or more biologics. 1 U-EXCEED is the first of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe Crohn's disease. 1

"The data from this first Phase 3 induction study in Crohn's disease suggest upadacitinib may help address the needs of patients suffering from this disease, as demonstrated in stringent endpoints such as endoscopic response," said Michael Severino , M.D., vice chairman and president, AbbVie. "We continue to leverage our expertise in IBD by driving research and development that help shape the IBD landscape and elevate standards of care for patients."

read more Show less
Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in securities class action lawsuits against Bristol-Myers Squibb Company if they received Contingent Value Rights in exchange for their shares of Celgene Corporation pursuant to BMS' acquisition of Celgene on November 20, ...

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in securities class action lawsuits against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE:BMY), if they received Contingent Value Rights ("CVRs") in exchange for their shares of Celgene Corporation pursuant to BMS' acquisition of Celgene on November 20, 2019. These actions are pending in the United States District Court for the Southern District of New York

What You May Do

read more Show less

MARKETS

Markets
TSX21077.35-85.30
TSXV924.67+4.12
DOW35754.75+35.32
S&P 5004701.21+14.46
NASD15786.99+100.07
ASX7313.90+68.80

COMMODITIES

Commodities
Gold1784.37+1.00
Silver22.40-0.03
Copper4.37-0.02
Palladium1864.50+17.50
Platinum959.00+2.00
Oil72.67+0.31
Heating Oil2.27+0.01
Natural Gas3.83+0.02